Recently, new sensitive methods have been proposed to determine hyaluronic acid in serum, either by radioimmunoassay I or by an irnmunoenzyrnoassay.' The immunoenzymoassay was based on the specific binding of a glycoprotein, hyaluronectin, to hyaluronic acid. Other glycosaminoglycans were shown not to interfere in the assay. The blocking of hyaluronectin binding to hyaluronic acid coated plates by soluble hyaluronic acid allowed the quantitation of hyaluronic acid in biological fluids.
The validity of that method for pleural and ascitic fluids was demonstrated by testing 53 samples (49 pleural fluids and four ascitic fluids) including four pleural and one peritoneal mesotheliomas. Their hyaluronic acid content was determined by the immunoenzymoassay as well as by the electrophoretic method routinely used for the diagnosis of mesothelioma.
The electrophoretic method required a 72 hour proteolytic digest of 10 mL sample (pronase, streptomyces griseus, Sigma, St Louis, Missouri, USA, type XIV, O' 5 mg/rnl, in Tris 0·1 M, CaCI 2 0·4 mM, pH 8'6) before dialysis against running water for 8 hours. The hyaluronic acid was then precipitated by three volumes of a mixture of sodium acetate/ethanol (1/3 v/v) at 4°C overnight. The precipitate was collected by centrifugation, dried and dissolved in distilled water. The recovery of hyaluronic acid extraction was 79%. Quantitation of hyaluronic acid was performed by electrophoresis, as previously descri bed. ]
Immunoenzymoassay was performed as previously described? except that incubation of samples with hyaluronectin was carried out in plates at 37°C. As shown previously, incubation at 37°C lowers the hyaluronectin-hyaluronic acid affinity, thus permitting measurement of hyaluronic acid at higher concentrations without Correspondence: Dr J Bertrand.
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increasing the concentration of hyaluronectin in the reagent. In the experiments reported here, pleural fluids were diluted 1/10 and 1/100 and incubated overnight at 37°C with protease. Protease was denaturated by heating at 100°C for 20 min in an oil-bath. Diluted samples were assayed in duplicate. Standards were made with hyaluronic acid (Fluka, Buchs, Switzerland) chondroitinase and protease digested as described/ then diluted to give concentration of 12,8, 604, 3,2, 1'6, 0,8, 004 and 0·2mg/L. A control protease denaturation was included on each plate. The overall time required for the assay was 40 hours. The relation between the two methods is shown in Fig. I .
Including all the data, the correlation coefficient was 0·985 with a high significance (P < 0-0001). Excluding the highest value, the correlation coefficient was slightly lower (0'944) with the same degree of significance. The immunoenzymoassay yields higher values than the electrophoretic method (equation of the regression time: y = 1·30x -7,52). This is presumably due to the fact that the immunoenzymoassay has fewer purification steps and therefore minimises procedural loss of material.
These results showed that the immunoenzymoassay could be used to quantify hyaluronic acid in pleural and ascitic fluids, as a clinical parameter for the diagnosis of malignant mesothelioma. !:~~~m-------;;; FIGURE I. Linear regression curve obtained after determination ofthe hyaluronic acid content ofthe samples by immunoenzymoassay and by an electrophoretic method.
